A A Mathias

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen
    Anita A Mathias
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:167-73. 2007
  2. ncbi Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir
    Anita A Mathias
    Clinical Research, Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 49:156-62. 2008
  3. ncbi Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure
    A A Mathias
    Clinical Research, Gilead Sciences, Inc, Foster City, California, USA
    Clin Pharmacol Ther 85:64-70. 2009
  4. ncbi Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity
    A A Mathias
    Gilead Sciences, Inc, Foster City, California, USA
    Clin Pharmacol Ther 87:322-9. 2010

Detail Information

Publications4

  1. ncbi Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen
    Anita A Mathias
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:167-73. 2007
    ....
  2. ncbi Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir
    Anita A Mathias
    Clinical Research, Gilead Sciences Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 49:156-62. 2008
    ..Two studies evaluated pharmacokinetic (PK) interactions among EVG and RTV-boosted tipranavir (TPV/r) or darunavir (DRV/r)...
  3. ncbi Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure
    A A Mathias
    Clinical Research, Gilead Sciences, Inc, Foster City, California, USA
    Clin Pharmacol Ther 85:64-70. 2009
    ..Elvitegravir and ritonavir were generally well tolerated in this study. These data provide a critical understanding of ritonavir's dose-response relationship for inhibition of CYP3A activity in humans...
  4. ncbi Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity
    A A Mathias
    Gilead Sciences, Inc, Foster City, California, USA
    Clin Pharmacol Ther 87:322-9. 2010
    ....